Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

C7R-expressing EBVSTs

A preparation of human Epstein-Barr virus (EBV)-specific T lymphocytes (EBVSTs) that have been genetically modified to express the constitutively active interleukin 7 (IL-7) receptor (C7R; IL-7R), with potential immunostimulating and antineoplastic activities. Upon administration, the CR7-expressing EBVSTs specifically recognize and bind EBV-infected tumor cells, resulting in tumor cell lysis. EBV, a ubiquitous human herpes virus, is associated with various malignancies, specifically nasopharyngeal carcinoma and lymphomas, including Hodgkin and non-Hodgkin. C7R triggers IL-7-mediated signaling that promotes T-cell proliferation and survival. The enhanced T-cell survival prolongs EBV-infected tumor cell killing and anti-tumor activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:C7R modified EBV specific T lymphocytes
C7R-EBV T cells
C7R-expressing EBV-specific T lymphocytes
C7R-expressing Epstein-Barr virus-specific T lymphocytes
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search